May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Aqueous Humor Kinetics of Erythromycin After a Single-Dose Infusion: A Strategy to Improve Ocular Bioavailability by Modulating Efflux With Corticosteroids
Author Affiliations & Notes
  • S. Hariharan
    School of Pharmacy, UMKC, Kansas City, Missouri
  • S. Gunda
    School of Pharmacy, UMKC, Kansas City, Missouri
  • D. Pal
    School of Pharmacy, UMKC, Kansas City, Missouri
  • A. K. Mitra
    School of Pharmacy, UMKC, Kansas City, Missouri
  • Footnotes
    Commercial Relationships S. Hariharan, None; S. Gunda, None; D. Pal, None; A.K. Mitra, None.
  • Footnotes
    Support R01 EY 09171-12 and R01 EY 10659-10
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4321. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Hariharan, S. Gunda, D. Pal, A. K. Mitra; Aqueous Humor Kinetics of Erythromycin After a Single-Dose Infusion: A Strategy to Improve Ocular Bioavailability by Modulating Efflux With Corticosteroids. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4321.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Macrolides like Erythromycin are used to treat bacterial keratitis, but their ocular bio-availability is limited by the presence of functionally active P-glycoprotein (P-gp) on rabbit corneal epithelium. Hence, the objective was to study the aqueous humor kinetics of Erythromycin and its interaction with P-gp by co-administering with corticosteroids in a rabbit model utilizing anterior chamber microdialysis.

Methods:: Male New Zealand albino rabbits were anaesthetized and linear microdialysis probes were implanted into anterior chamber of the eye and perfused with isotonic phosphate buffer saline at 2µl/min. A well was placed over the cornea using bonding cement as a surgical adhesive agent. Ten µCi/ml solution of [14C]Erythromycin with a volume of 150µl was placed in the well for 2hrs. After 2hrs the solution and the well were removed. Microdialysis samples were collected every 20mins and analyzed using liquid scintillation counter. Experiments were repeated with topical infusions of [14C]Erythromycin in presence of Cyclosporine A (20µM, positive control) and corticosteroids like Methyl Prednisolone, Prednisolone and Prednisone (each at 500µM) which act as P-gp inhibitors. Cytotoxicity studies for these inhibitors were conducted using cultured rabbit primary corneal epithelial cells.

Results:: Pharmacokinetic parameters like area under concentration-time curves (AUC0-), Cmax and Clast of [14C]Erythromycin after a single-dose infusion were 140.5±53 µg*min/ml, 0.55±0.15 µg/ml and 0.11±0.06 µg/ml respectively. Maximum inhibition of P-gp mediated efflux was observed with 500µM Methyl Prednisolone with approximately 4 times higher AUC0- compared with control. Cmax and Clast were almost 5 and 3 times higher respectively for Erythromycin with 500 µM Methyl Prednisolone when compared to control. Pharmacokinetic parameters for Erythromycin with 500 µM Prednisolone and Prednisone showed more than 2 times higher (AUC0-), Cmax and Clast when compared to control. Rate of eliminations (k10) for erythromycin and those with inhibitors were not found to be statistically different. Cytotoxicity studies showed that all inhibitors were non-toxic at the concentration used.

Conclusions:: Ocular bioavailability of Erythromycin could be improved by co-administering with corticosteroids which are anti-inflammatory agents and P-gp inhibitors. Since bacterial infections are invariably associated with inflammation, co-administration of Erythromycin with corticosteroids will impart an efficient therapeutic response.

Keywords: cornea: epithelium • keratitis • anterior segment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×